Drugs / CB-012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06128044 | Feb 2024 → May 2025 | acute myeloid leukemia | Caribou Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06128044 ↗ |
| Modality | Cell therapy | “CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy” NCT06128044 ↗ |